Operationalization of Radium-223 Therapy for Bone Metastases - Eric Rohren

An excerpt from Dr. Eric Rohren's state of the art presentation on Radium-223.  This discussion includes the operationalization of Radium-223 at MD Anderson. In addition, a review of different agents available for imaging skeletal metastases with metastatic castration-resistant prostate cancer and a look at patient prognosis and survival data.


Biography:

Eric Rohren, MD. PhD., a national leader in radiology and nuclear medicine, has been chair of radiology at Baylor College of Medicine since October 1, 2015.   

Previously Dr. Rohren served as a professor in the Departments of Nuclear Medicine and Diagnostic Radiology, Division of Diagnostic Imaging, at the University of Texas MD Anderson Cancer Center and was chief of the Section of Positron Emission Tomography (PET).

Dr. Rohren has held leadership positions in several national groups, including the American College of Radiology, the Radiologic Society of North America, the American Board of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging. His research interests include cancer imaging, novel radiotracers in oncology and neurology and targeted radioisotope therapies. He has worked extensively on PET/CT reporting and has developed guidelines for report structure and content through his work with the PET Utilization Task Force.   

Dr. Rohren received his bachelor’s degree from St. Olaf College in Northfield, Minn., and earned his medical degree from Mayo Medical School in Rochester, Minn., and his doctorate from Mayo Graduate School in Immunology. He completed residency in diagnostic radiology and fellowship training in nuclear medicine at Duke University Medical Center in Durham, N.C., and is board certified by the American Board of Radiology and the American Board of Nuclear Medicine.

Dr. Rohren was on the MD Anderson faculty from 2007 until his appointment at Baylor College in 2015 and prior to that held appointments as a faculty physician at the Mayo Clinic and as medical director of several molecular imaging centers in Florida.